Lisata Therapeutics
110 Allen Road, 2nd Floor
Basking Ridge
New Jersey
07920
United States
Tel: 908-842-0100
443 articles about Lisata Therapeutics
-
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
4/23/2024
Lisata Therapeutics, Inc. announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (“mPDAC”).
-
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
4/9/2024
Lisata Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1.
-
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
4/3/2024
Lisata Therapeutics, Inc. today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April.
-
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaAchieves critical first step toward priority review voucher
3/21/2024
Lisata Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to LSTA1, the Company’s lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.
-
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
2/29/2024
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.
-
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
2/22/2024
Lisata Therapeutics, Inc. today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
-
Lisata Therapeutics to Present at BIO CEO & Investor Conference
2/20/2024
Lisata Therapeutics, Inc. today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.
-
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico - January 18, 2024
1/18/2024
Lisata Therapeutics, Inc. today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will deliver a company presentation at the upcoming Sequire Investor Summit being held January 23-25, 2024.
-
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
1/17/2024
Lisata Therapeutics, Inc. today announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”).
-
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
1/4/2024
Lisata Therapeutics, Inc. today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination with the standard-of-care therapy in Oncology & Cancer Case Reports Journal on December 30, 2023.
-
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
8/10/2022
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd.(“Roche”) to evaluate Cend’s lead investigational drug, CEND-1.
-
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, reported financial results for the three and six months ended June 30, 2022 and provided a business update.
-
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseTop-line data from all subjects expected by the first quarter of 2023
8/2/2022
Caladrius Biosciences, Inc. announced today the completion of enrollment and dosing in its Phase 1b, open-label, proof-of-concept study of CLBS201, a CD34+ regenerative cell therapy investigational product for intra-renal artery administration, for the treatment of diabetic kidney disease.
-
Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
7/28/2022
Caladrius Biosciences, Inc. today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT).
-
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology
7/6/2022
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that The Lancet Gastroenterology and Hepatology has published data from the Phase 1b study of CEND-1.
-
Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
6/9/2022
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announces that its merger partner in the creation of Lisata Therapeutics (“Lisata”), Cend Therapeutics, Inc. (“Cend”) today indicated that the first patient has been treated in the Phase 2b study of CEND-1 in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma.
-
Caladrius Biosciences to Present at the BIO International Convention 2022
6/8/2022
Caladrius Biosciences, Inc. announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
-
Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
5/26/2022
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that data highlighting the ongoing clinical Phase 1b/2b study of CEND-1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held from June 3–7, 2022 in Chicago, Illinois.
-
Caladrius Biosciences announced it was suspending enrollment in its Phase IIb FREEDOM study assessing xowna for coronary microvascular dysfunction (CMD) due to supply chain issues.
-
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
5/23/2022
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as the FREEDOM Trial, for the treatment of coronary microvascular dysfunction (“CMD”).